Device Trial Radar · NCT00262119
MINERVA: MINimizE Right Ventricular Pacing to Prevent Atrial Fibrillation and Heart Failure
Last checked: Nov 20, 2026Latest source record: Jul 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,300
Actual
Start
Feb 2006
Primary completion
Apr 2012
Study completion Apr 2013
Sponsor
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart FailurePublic (MDT)
- Sponsor type
- Industry
- First posted
- Dec 6, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to test the impact of the managed ventricular pacing (MVP) mode and atrial preventive and antitachycardia pacing therapies on the reduction of a composite clinical outcome composed of any death, permanent atrial fibrillation, and cardiovascular hospitalizations.
Conditions
- Atrial Fibrillation
- Heart Failure, Congestive
Interventions
Pacemaker Medtronic EnRhythmDevice
Pacemaker specific programming
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite Endpoint Composed by Death for Any Cause, Cardiovascular Hospitalization or Permanent AF at 2 YearsTime frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medtronic Italia S.p.A.
Rome, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.